Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer

被引：0
|
作者：
Hakon Blomstrand
Ursula Scheibling
Charlotte Bratthäll
Henrik Green
Nils O. Elander
机构：
[1] Ryhov County Hospital,Department of Oncology
[2] Linköping University,Division of Oncology, Department of clinical and experimental medicine, Faculty of medicine and health sciences
[3] Kalmar County Hospital,Department of Oncology
[4] Linköping University,Division of Drug Research, Department of Medical Health Sciences
[5] Department of Forensic Genetics and Forensic Toxicology,undefined
[6] National Board of Forensic Medicine,undefined
来源：
BMC Cancer | / 19卷
关键词：
Pancreatic cancer; Chemotherapy; Gemcitabine; Nab-paclitaxel; Bone marrow toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] EFFICACY OF GEMCITABINE/NAB-PACLITAXEL INDUCTION CHEMOTHERAPY FOLLOWED BY CHEMORADIOTHERAPY FOR UNRESECTABLE LOCALLY ADVANCED PANCREATIC CANCER
    Takada, Ryoji
    Ikezawa, Kenji
    Kiyota, Ryosuke
    Imai, Toshihiro
    Yutaro, Abe
    Fukutake, Nobuyasu
    Takatoshi, Nawa
    Katayama, Kazuhiro
    Ohkawa, Kazuyoshi
    GASTROENTEROLOGY, 2020, 158 (06) : S865 - S866
  • [22] Effects and Problems of Neoadjuvant Chemotherapy Using Gemcitabine plus Nab-Paclitaxel for Advanced Pancreatic
    Tomita, K.
    Chiba, N.
    Nakagawa, M.
    Koganezawa, I.
    Yokozuka, K.
    Ozawa, Y.
    Kobayashi, T.
    Sano, T.
    Tsutsui, R.
    Kawachi, S.
    PANCREAS, 2019, 48 (10) : 1537 - 1537
  • [23] Predictors of vulnerability to nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer
    Iede, Kiyotsugu
    Yamada, Terumasa
    Tominaga, Shusei
    ANNALS OF ONCOLOGY, 2023, 34 : S1453 - S1453
  • [24] Gemcitabine plus Nab-Paclitaxel with chemoradiation in locally advanced pancreatic cancer (LAPC)
    Olowokure, Olugbenga
    Torregroza-Sanchez, Maria Patricia
    Bedoya-Apraez, Ivan Dario
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2013, 4 (02) : E16 - E18
  • [25] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
    Tsujimoto, Akiko
    Sudo, Kentaro
    Nakamura, Kazuyoshi
    Kita, Emiri
    Hara, Ryusuke
    Takayama, Wataru
    Ishii, Hiroshi
    Yamaguchi, Taketo
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [26] Effect of nab-paclitaxel combination chemotherapy on response and survival in pancreatic cancer
    Dean, Andrew Peter
    Cooray, Prasad
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Phase I trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer.
    Mahipal, Amit
    Springett, Gregory M.
    Burke, Nancy
    Bertels, Barbara
    Wapinsky, Georgine
    Almhanna, Khaldoun
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [28] Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study
    Li, Haorui
    Guo, Yu
    Sun, Xugang
    Lu, Yang
    Chang, Shaofei
    Wang, Xiuchao
    Gao, Song
    Gao, Chuntao
    Zhao, Tiansuo
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [29] Gemcitabine and Nab-paclitaxel Induced Complete Response of Advanced Pancreatic Tail Cancer
    Hirakawa, N.
    Itoi, T.
    Sofuni, A.
    Tsuchiya, T.
    Ishii, K.
    Tanaka, R.
    Tonozuka, R.
    Mukai, S.
    Yamamoto, K.
    Asai, Y.
    Matsunami, Y.
    Homma, T.
    Nakatsubo, R.
    PANCREAS, 2021, 50 (07) : 1065 - 1065
  • [30] Survival of patients with advanced pancreatic cancer is increased by nab-paclitaxel plus gemcitabine
    Nature Reviews Gastroenterology & Hepatology, 2013, 10 (12) : 695 - 695
12345